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ABSTRACT A key event in Ras-mediated signal trans-
duction and transformation involves Ras interaction with its
downstream effector targets. Although substantial evidence
has established that the Raf-1 serine/threonine kinase is a
critical effector of Ras function, there is increasing evidence
that Ras function is mediated through interaction with mul-
tiple effectors to trigger Raf-independent signaling pathways.
In addition to the two Ras GTPase activating proteins (GAPs;
p120- and NFl-GAP), other candidate effectors include acti-
vators of the Ras-related Ral proteins (RalGDS and RGL) and
phosphatidylinositol 3-kinase. Interaction between Ras and
its effectors requires an intact Ras effector domain and
involves preferential recognition of active Ras-GTP. Surpris-
ingly, these functionally diverse effectors lack significant
sequence homology and no consensus Ras binding sequence
has been described. We have now identified a consensus Ras
binding sequence shared among a subset of Ras effectors. We
have also shown that peptides containing this sequence from
Raf-1 (RKTFLKLA) and NFl-GAP (RRFFLDIA) block NFl-
GAP stimulation of Ras GTPase activity and Ras-mediated
activation of mitogen-activated protein kinases. In summary,
the identification of a consensus Ras-GTP binding sequence
establishes a structural basis for the ability of diverse effector
proteins to interact with Ras-GTP. Furthermore, our dem-
onstration that peptides that contain Ras-GTP binding se-
quences can block Ras function provides a step toward the
development of anti-Ras agents.
Ras proteins are GDP/GTP binding proteins that function as
molecular switches by relaying signaling events from the cell
surface to the nucleus, thus regulating cell growth and differ-
entiation (1, 2). Ras function is regulated by guanine nucleo-
tide exchange factors that promote formation of active Ras-
GTP and by GTPase activating proteins (GAPs; p120- and
NFl-GAP) that promote formation of inactive Ras-GDP
(3-5). Oncogenic Ras mutants are defective in GAP respon-
siveness and are chronically GTP-bound, resulting in consti-
tutive activation of Ras-mediated signaling events that pro-
mote the aberrant growth of tumor cells.
It is now clear that the c-Raf-1 serine/threonine kinase
functions as a downstream effector for promoting Ras-
triggered activation of the mitogen-activated protein kinase
(MAP kinase) pathway (1, 2). However, there is increasing
evidence that Ras function is also mediated by Raf-
independent signaling pathways (6). For example, Wigler and
colleagues (7) have recently identified an effector domain
mutant of oncogenic Ras that does not bind Raf-1 yet retains
a signaling activity required for Ras transformation. Further-
more, the increasing number of putative Ras effectors also
provides support for the existence of Raf-independent Ras
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signaling pathways. These include p120- and NFl-GAP, two
guanine nucleotide exchange factors and activators of Ral
proteins (RalGDS and RGL) (8-10), phosphatidylinositol
3-kinase (11), MAP kinase/ERK kinase kinase 1 (MEKK1)
(12), Rini (13), and the Schizosaccharomyces pombe proteins
Scdl (a Rho guanine nucleotide exchange factor) and Byr2 (a
serine/threonine kinase) (14). Like Raf-1, these structurally
and functionally diverse proteins exhibit preferential binding
to Ras-GTP and these interactions are dependent on an intact
Ras effector domain (residues 32-40). Mutations in the Ras
effector domain impair both Ras transforming activity and
interaction with these effector proteins. While the importance
of Raf-1 in mediating Ras function is well-established, the
precise roles of these other putative Ras effectors in Ras
function remain to be determined.
Since high-affinity binding to Ras-GTP requires a small
region surrounding the Ras effector domain (residues 26-48)
(15), it is plausible that the complementary effector contacts
also employ a compact region. Surprisingly, many putative Ras
effectors lack significant sequence homology, and attempts to
identify a common framework containing recognition ele-
ments for binding Ras-GTP have been unsuccessful. However,
the inability to identify a consensus binding sequence shared
among dissimilar Ras effectors may instead reflect the inability
of sequence comparison algorithms to correctly identify a
small consensus motif in the context of large input sequences.
Consequently, we initiated studies to identify more restricted
Ras-GTP binding sequences that could be more effectively
analyzed for sequence homology. In this study, we describe the
identification of a consensus Ras-binding sequence that is
shared among a subset of Ras effectors. Furthermore, we show
that peptides containing this sequence from Raf-1 and NFl-
GAP can inhibit Ras interaction with NFl-GAP and Raf-1.
MATERIALS AND METHODS
Cell Culture and Transformation Analysis. NIH 3T3 cells
were grown in Dulbecco's modified Eagle's medium supple-
mented with 10% (vol/vol) calf serum. DNA transfections
were performed by using the calcium phosphate precipitation
technique. Cells were transfected with pZIP-rasH plasmid
DNAs encoding oncogenic H-Ras (12V or 61L) (10 or 50 ng
per dish), either alone or with 2 ,ug of the empty pZIP-
NeoSV(x)1 retrovirus vector plasmid or plasmid constructs
encoding Raf-Cys (pCGN-raf-Cys) (16) or NF1-56 (pZIP-
NF1-56). Transfections were performed in triplicate, and
transformed foci were quantitated after 14-16 days. Relative
focus-forming units shown are normalized to the activities of
Abbreviations: MAP kinase, mitogen activated protein kinase;
MEKK1, MAP kinase/ERK kinase kinase 1; GAP, GTPase activating
protein; GST, glutathione S-transferase.























Proc. Natl. Acad. Sci. USA 93 (1996)
oncogenic Ras (3-6 x 103 foci per j,g of transfected plasmid
DNA).
Expression and Purification of Ras and Glutathione S-
Transferase (GST)-Raf Fusion Proteins. Expression and pu-
rification of bacterially expressed H-Ras protein was per-
formed as described (17). Complex formation of Ras and
guanosine 5'[3,,y-methylene]triphosphate, a nonhydrolyzable
GTP analog (Boehringer Mannheim), has been described (18).
Both NF1-56 and Raf-Cys were prepared as GST fusion
proteins, as described (19).
Enzyme-Linked Immunosorbent Assay (ELISA). In vitro
Ras binding interactions were measured by incubating 100
pmol of GST fusion protein and corresponding amounts of
GST bound to 96-well microtiter plates with H-Ras complexed
to guanosine 5'-[P,y-methylene]triphosphate or GDP at con-
centrations from 31 nM to 2 ,uM as described (16).
Synthesis of Peptides. Peptides were synthesized by the
UNC/PMBB Facility by using standard solid-phase methods
and purified by reverse-phase HPLC. All amides were acety-
lated at their NH2 termini. Peptide sequences are as follows
(consensus sequence residues are underlined): Raf-L, CN-
FARKTFLKLAFC; Raf-L-Scram, FFNCACLKAFRHATK;
Raf-S, FARKTFLKLAF; Raf-S-Scram, AKFLRLFKFAT;
NF1-L, CNFDAARRFFLDIASC; NF1-S, ARRFFLDIAD;
NFl-S-Scram, DFLRIFRADA. The Raf-L and NF1-L pep-
tides were synthesized with one additional cysteine at the NH2
terminus so that constrained peptides could be generated.
NF1-GRD GAP Inhibition Assay. GTPase activity was
determined using 4 nM [,y-32P]GTP-labeled Ras, 0.2 nM
NF1-GRD, and various concentrations of peptides as de-
scribed (20). The amount of phosphate released was quanti-
tated by scintillation counting, after an organic extraction in
the presence of ammonium molybdate. Assays were per-
formed three times in duplicate.
Oocyte Lysate MAP Kinase Assay. Preparation of Xenopus
oocyte lysate and the Ras-mediated activation of MAP kinase
assay were done as described (21-23). Assays were performed
with H-Ras(61L) (5 jig/ml) and 35 p,M synthesized peptide.
A
Peptide concentrations were determined by amino acid com-
position analysis of peptide stock solutions by the Protein
Chemistry Laboratory (Univ. of North Carolina, Chapel Hill-
National Institute of Environmental Health Sciences). Briefly,
oocyte lysate, an ATP regeneration system, Ras, and the
appropriate peptide were incubated at 20°C for 2 hr. The
reaction was then stopped and frozen. One-third of the
reaction mixture was then added to a kinase assay system with
an excess of myelin basic protein as the substrate. After
incubation for 20 min at 20°C, the reaction was stopped and
resolved by SDS/polyacrylamide gel electrophoresis. The de-
gree of activation of MAP kinase at a given time point for a
given sample was measured by the relative incorporation of 32p
by the myelin basic protein substrate and was quantitated by
autoradiography and AMBIS , scanning.
RESULTS
Identification of a Consensus Ras Binding Sequence in
Raf-Cys and NF1-56. To determine whether Raf-1 and other
Ras effectors shared a consensus Ras-binding sequence, we
first wanted to more precisely determine and characterize the
sequences of NFl-GAP and Raf-1 that were involved in Ras
binding. We concentrated our analyses on 48- and 56-amino
acid fragments from Raf-1 and NFl-GAP, designated Raf-Cys
and NF1-56, respectively (Fig. IA). We have recently shown
that Raf-Cys, corresponding to the cysteine-rich domain
(Raf-1 residues 139-184), shows high-affinity GTP-dependent
binding to Ras in vitro and antagonizes Ras function in vivo
(16). NF1-56 is derived from the 334-amino acid GAP-related
domain of NFl-GAP, designated NF1-GRD. NF1-GRD ex-
hibits the same abilities as NFl-GAP to bind to Ras and
stimulate its GTPase activity (4). Although the interaction of
NF1-56 and Ras has not been observed previously, the ex-
pression of this fragment in Ras-transformed cells reduced
their ability to form colonies in soft agar (24), suggesting that
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FIG. 1. Diagram and sequences of Ras-binding frag-
ments and peptides from Raf-1 and NFl-GAP. (A) Arrow
indicates location of Raf-Cys and NF1-56 in Raf-1 and
NFl-GAP, respectively. (B) Regions of Raf-Cys and
NF1-56 sharing high sequence similarity and a comparison
of Ras-GTP recognition sequences contained in Raf and
GAP family members. Sequence alignment and data base
searches were performed by using the Sequence Analysis
Software Package from Genetics Computer, Inc. (the GCG
Package). Homologous sequences are boxed. Numbers in-
dicate residue positions in the full-length proteins. GenBank
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Therefore, we utilized two approaches to evaluate NF1-56
interaction with Ras (16).
First, as we have described (16) for Raf-Cys, we observed
that cotransfection of NF1-56 with oncogenic Ras resulted in
efficient (-70%) inhibition of Ras focus-forming activity (Fig.
2A). To demonstrate that this inhibitory activity results from
an inactive complex between NF1-56 and Ras, we utilized an
in vitro ELISA as described (16). NF1-56, like Raf-Cys, showed
high-affinity preferential binding to GTP-complexed Ras (Fig.
2B). Therefore, the NFl-GAP and Raf-1 fragments employed
here contain the shortest sequences that have been shown to
be capable of interacting with active Ras-GTP and blocking its
transforming activity in mammalian cells.
Our demonstration that Raf-Cys and NF1-56 share common
Ras binding properties provided us with two small fragments
with which to search for a common Ras-binding sequence.
Using the GCG BESTFIT algorithm, we identified a contiguous
stretch of 8 amino acids shared between Raf-Cys and NF1-56
displaying 75% amino acid similarity (Fig. 1B). Since no
additional sequence homologies were detected, we anticipated
that this represented a consensus Ras-binding sequence. To
address this possibility, we synthesized short amino acid pep-
tides corresponding to these sequences from NFl-GAP and
Raf-1 and then determined their abilities to antagonize Ras-
effector interactions.
Peptides Containing the Consensus Ras Binding Sequence
from Raf-1 and NFl-GAP Inhibit Ras-Effector Interactions.
To determine whether these peptides could inhibit the ability
of NFl-GAP to stimulate the intrinsic GTPase activity of Ras,
we utilized NF1-GRD, which contains the catalytic domain
responsible for Ras binding and Ras GTPase stimulation. We
observed that 14- to 16-amino acid peptides corresponding to
the putative Ras binding sequences of both Raf-1 (designated
Raf-L; Fig. 3) and NFl-GAP (NF1-L; data not shown) were
potent inhibitors of NF1-GRD stimulation. In contrast, a
control peptide containing the identical amino acid content of
Raf-L but scrambled in sequence (Raf-L-Scram) showed no
inhibition of NF1-GRD. Comparable inhibition was also ob-
served with shorter 10- to 11-amino acid peptides containing
the consensus sequence (Raf-S and NFl-S peptides; data not
shown). The concentrations required for 50% inhibition of
NFl-stimulated Ras GTPase activity were found to be 86.5 ±
8.9 ,iM and 44.4 ± 6.6 ,uM, for NFl-S and Raf-S, respectively.
Since NF1-GRD interaction with Ras is dependent on an
intact Ras effector domain, these results suggest that both














We next determined whether these peptides could antago-
nize oncogenic Ras activation of p42 and p44 MAP kinases by
using an in vitro Xenopus oocyte lysate assay (3). It has been
shown that addition of oncogenic Ras protein to oocyte lysates
results in a Raf-dependent activation of MEK and MAP
kinases (21-23). The addition of either Raf-1 or NFl-GAP
peptide showed potent inhibition of MAP kinase activation at
concentrations of 35 ,LM (>75%), whereas the control peptide
showed no inhibition (Fig. 4). These results suggest that
peptides derived from the consensus sequence of Raf-Cys and
NF1-56 prevented Ras-mediated activation of Raf-1, thus
preventing activation of MAP kinases.
Having identified a putative functional Ras-GTP recogni-
tion motif, we performed data base searching to identify this
consensus sequence in other mammalian and yeast Ras GAPs
(IRA1, IRA2, and SarGAP) and in other Raf kinase family
members (A-Raf, B-Raf, and D-Raf) (Fig. 1B). With the
exception of p120-GAP, the first 2 residues in the consensus
sequence contain either lysine or arginine. The absence of a
basic residue at position 1 may explain why p120-GAP pos-
sesses a lower affinity for Ras-GTP relative to other Ras
effectors. Position 4 requires phenylalanine or leucine,
whereas hydrophobic amino acids are preferred at positions 5
and 7. Conservation of alanine at position 8 suggests this
residue is important for Ras binding.
DISCUSSION
Although substantial experimental evidence has established a
critical role of the Raf-1 serine/threonine kinase as a down-
stream effector for Ras signal transduction and transforma-
tion, there is increasing evidence that Ras function may also
require stimulation of Raf-independent signaling pathways.
The possibility that Ras function is triggered via its interaction
with multiple effectors is supported by the identification of
increasing numbers of candidate downstream effectors for
Ras. Included among these are the two Ras GAPs, phosphati-
dylinositol 3-kinase, the MEKK1 serine/threonine kinase, and
two Ral guanine nucleotide exchange factors (4, 8-12). Like
Raf-1, each of these proteins show preferential association
with active Ras-GTP and this binding requires an intact Ras
effector domain. Surprisingly, sequence homology analyses
showed no common sequences in these structurally and func-
tionally diverse proteins that would mediate interaction with
activated Ras-GTP. Therefore, it has been assumed that Ras
effectors do not share a common sequence motif involved in
Ras binding. However, in the present study, we have identified



















FIG. 2. Interaction of Raf-Cys and NF1-56 with Ras in vivo and in vitro. (A) Cotransfection of Raf-Cys or NF1-56 significantly reduces Ras(61L)
focus-forming activity. FFU, focus-forming units. (B) NF1-56 preferentially binds to Ras-GTP. Ras concentrations required for half-maximal
binding (C1/2) to 100 pmol of plated Raf-Cys and NF1-56 were compared. All experiments were performed in triplicate with GST (control)
absorbance values subtracted from the absorbance of GST-Raf and GST-NF1 proteins.
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FIG. 3. Consensus Ras-binding sequence peptides inhibit NF1-GRD-stimulated Ras GTPase activity. Raf-L, but not the scrambled peptide
control at 250 ,uM, shows complete inhibition of NF1-GRD stimulation of H-Ras GTPase activity. The results represent two assays that were
performed in triplicate. NF1-GRD competition experiments were also conducted on the following peptides: NF1-L, Raf-S, Raf-S-Scram, NF1-S,
and NFl-S-Scram. All reactions contained Ras and the following additions: 0, no addition, 0, NF1-GRD only; A, Raf-L-Scram only; *, NF1-GRD
+ Raf-L-Scram; o, Raf-L only; O, NF1-GRD + Raf-L.
of Ras effectors. The importance of this sequence is demon-
strated by the ability of peptides that contain the consensus
sequence from Raf-1 and NFl-GAP to block functional in-
teraction with these two effectors.
Although the region encompassing Raf-1 amino acids 51-
131 clearly defines a minimal Ras binding sequence (25), we
recently determined that the Raf-1 cysteine-rich domain (res-
idues 139-184) represents a second Ras binding sequence in
the NH2 terminus of Raf-1 (16). The existence of a second Ras
binding domain was unexpected since a single amino acid
substitution at Raf-1 residue 89 is sufficient to abolish Ras-Raf














FIG. 4. Consensus Ras binding sequence peptides inhibit onco-
genic Ras activation ofMAP kinases in vitro. MAP kinase activity was
measured by phosphorylation of exogenous myelin basic protein. Data
from three experiments were averaged, with each condition done in
triplicate. Representative data from one experiment are shown below.
Background counts were subtracted from cpm determinations at 2 hr.
crystal structure of Raf-1 residues 51-131 with the Ras-related
protein RaplA (which shares complete identity with Ras
residues 32-40) implicated a direct interaction between these
Raf-1 residues and the Ras effector domain (27). However, we
have recently established that Raf-Cys contains a cryptic Ras
binding site in unstimulated Raf-1 and that Ras interaction
with both Ras binding sites are required for Ras transforma-
tion (28, 30). Furthermore, our demonstration that peptides
containing the consensus Ras binding sequence can block Ras
activation of the MAP kinase cascade in vitro provides addi-
tional evidence that Ras interaction with Raf-Cys is required
for Ras-mediated activation of Raf. Thus, inhibition of Ras
interaction with either Ras binding domains of Raf-1 is likely
to be sufficient to impair the ability of Ras to mediate
activation of the Raf-1 kinase.
We have searched for this motif in other candidate Ras
effectors and identified similar sequences in mammalian
MEKK1 (GenBank accession no. A46212; residues 43-50),
RalGDS (GenBank accession no. 528415; residues 820-827),
as well as in yeast adenylate cyclase (GenBank accession no.
P08678; residues 951-958). MEKK1 has been shown to com-
plex with Ras and to be activated by a Ras-dependent pathway
(12, 28). In addition, both yeast adenylate cyclase and RalGDS
can associate with Ras and the consensus sequence is present
in RalGDS fragments that were identified in yeast two-hybrid
binding assays (8-10). However, the absence of this consensus
sequence in Rinl suggests that there are multiple Ras-binding
sequences in different Ras effectors. For example, we have
shown that two nonhomologous sequences in Raf-1 are capa-
ble of discriminating between active and inactive forms of Ras
(16). In summary, the identification of consensus Ras-GTP
recognition sequences establishes a structural basis for the
ability of functionally diverse proteins to recognize Ras-GTP.
The frequent association of mutated Ras with human tu-
mors has prompted considerable interest in identifying ap-
proaches to blocking Ras function for cancer treatment. For
example, peptide-based inhibitors of protein farnesyltrans-
ferase, which catalyzes the addition of a farnesyl isoprenoid to
Ras, have been developed and shown to be potent inhibitors
of Ras function (29). However, since such inhibitors also affect
other farnesylated proteins and since farnesylation is critical
for both normal and oncogenic Ras function, such compounds
may not preferentially antagonize oncogenic Ras. In contrast,
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since oncogenic, but not normal, Ras proteins persist in a
chronic GTP-complexed state, agents that show preferential
recognition of Ras-GTP may provide more effective ap-
proaches for selective blocking of oncogenic Ras proteins.
Thus, our demonstration that peptides containing a consensus
Ras-GTP binding sequence can block Ras function may
provide a step toward the development of anti-Ras agents.
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